| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | lapatinib | CCLE | pan-cancer | AAC | 0.43 | 4e-15 |
| mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.42 | 6e-14 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.27 | 5e-10 |
| mRNA | EKB-569 | GDSC1000 | pan-cancer | AAC | 0.27 | 1e-09 |
| mRNA | GSK269962A | GDSC1000 | pan-cancer | AAC | -0.25 | 1e-08 |
| mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.25 | 2e-08 |
| mRNA | CP724714 | GDSC1000 | pan-cancer | AAC | 0.25 | 3e-08 |
| mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.24 | 3e-08 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.24 | 6e-08 |
| mRNA | lapatinib | gCSI | pan-cancer | AAC | 0.34 | 1e-07 |